Compare ELF & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELF | TGTX |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 2016 | 1995 |
| Metric | ELF | TGTX |
|---|---|---|
| Price | $80.44 | $30.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $127.00 | $54.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 02-05-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.40 | ★ 2.78 |
| Revenue | ★ $1,385,640,000.00 | $531,898,000.00 |
| Revenue This Year | $20.59 | $87.88 |
| Revenue Next Year | $16.79 | $48.75 |
| P/E Ratio | $57.51 | ★ $11.08 |
| Revenue Growth | 13.80 | ★ 100.88 |
| 52 Week Low | $49.40 | $25.28 |
| 52 Week High | $150.99 | $46.48 |
| Indicator | ELF | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 46.32 |
| Support Level | $76.51 | $29.79 |
| Resistance Level | $82.19 | $31.37 |
| Average True Range (ATR) | 3.10 | 1.00 |
| MACD | 1.44 | 0.04 |
| Stochastic Oscillator | 71.68 | 47.47 |
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.